228 related articles for article (PubMed ID: 25403591)
21. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.
Hirakawa A; Wages NA; Sato H; Matsui S
Stat Med; 2015 Oct; 34(24):3194-213. PubMed ID: 25974405
[TBL] [Abstract][Full Text] [Related]
23. Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling.
Bottino DC; Patel M; Kadakia E; Zhou J; Patel C; Neuwirth R; Iartchouk N; Brake R; Venkatakrishnan K; Chakravarty A
Clin Cancer Res; 2019 Nov; 25(22):6633-6643. PubMed ID: 31320596
[TBL] [Abstract][Full Text] [Related]
24. Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.
Huang B; Bycott P; Talukder E
J Biopharm Stat; 2017; 27(1):44-55. PubMed ID: 26882496
[TBL] [Abstract][Full Text] [Related]
25. A comparison of model-free phase I dose escalation designs for dual-agent combination therapies.
Barnett H; George M; Skanji D; Saint-Hilary G; Jaki T; Mozgunov P
Stat Methods Med Res; 2024 Feb; 33(2):203-226. PubMed ID: 38263903
[TBL] [Abstract][Full Text] [Related]
26. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
[TBL] [Abstract][Full Text] [Related]
27. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
28. Innovations for phase I dose-finding designs in pediatric oncology clinical trials.
Doussau A; Geoerger B; Jiménez I; Paoletti X
Contemp Clin Trials; 2016 Mar; 47():217-27. PubMed ID: 26825023
[TBL] [Abstract][Full Text] [Related]
29. Risks and benefits associated with novel phase 1 oncology trial designs.
Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
[TBL] [Abstract][Full Text] [Related]
30. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
Shimamura F; Hamada C; Matsui S; Hirakawa A
J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
32. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Araujo D; Greystoke A; Bates S; Bayle A; Calvo E; Castelo-Branco L; de Bono J; Drilon A; Garralda E; Ivy P; Kholmanskikh O; Melero I; Pentheroudakis G; Petrie J; Plummer R; Ponce S; Postel-Vinay S; Siu L; Spreafico A; Stathis A; Steeghs N; Yap C; Yap TA; Ratain M; Seymour L
Ann Oncol; 2023 Jan; 34(1):48-60. PubMed ID: 36182023
[TBL] [Abstract][Full Text] [Related]
33. Bayesian adaptive clinical trials: a dream for statisticians only?
Chevret S
Stat Med; 2012 May; 31(11-12):1002-13. PubMed ID: 21905067
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
35. Rational design and identification of immuno-oncology drug combinations.
Iafolla MAJ; Selby H; Warner K; Ohashi PS; Haibe-Kains B; Siu LL
Eur J Cancer; 2018 May; 95():38-51. PubMed ID: 29631102
[TBL] [Abstract][Full Text] [Related]
36. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
37. A Bayesian hierarchal modeling approach to shortening phase I/II trials of anticancer drug combinations.
Yada S; Hamada C
Pharm Stat; 2018 Nov; 17(6):750-760. PubMed ID: 30112847
[TBL] [Abstract][Full Text] [Related]
38. Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Kramar A; Lebecq A; Candalh E
Stat Med; 1999 Jul; 18(14):1849-64. PubMed ID: 10407256
[TBL] [Abstract][Full Text] [Related]
39. Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.
Rami A; DuBois SG; Campbell K
Clin Trials; 2024 Apr; 21(2):211-219. PubMed ID: 37961910
[TBL] [Abstract][Full Text] [Related]
40. A Road Map for Designing Phase I Clinical Trials of Radiotherapy-Novel Agent Combinations.
Brown SR; Hinsley S; Hall E; Hurt C; Baird RD; Forster M; Scarsbrook AF; Adams RA
Clin Cancer Res; 2022 Sep; 28(17):3639-3651. PubMed ID: 35552622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
